According to the news released by the University of Helsinki in Finland on March 8th, Finnish researchers have developed a nasal COVID-19 vaccine and plan to conduct clinical trials in a few months.
According to reports, this nasal COVID-19 vaccine is an adenovirus vector vaccine, which is developed based on gene transfer technology. The researchers said that because COVID-19 can spread through the respiratory system, nasal injection of vaccine may cause a wider immune response than intramuscular injection.
Extended data:
Clinical trials of this vaccine are about to begin.
Participants in this vaccine research and development work include researchers from the University of Helsinki and the University of Eastern Finland, and the research and development team set up a company to promote this vaccine. It is reported that the company will conduct clinical trials of this vaccine in Finland in the next few months.
Sepo Yula-Hirtu Ala, a professor of molecular medicine at the University of Eastern Finland and head of the R&D team, told Xinhua that some countries provide financial support to researchers to ensure that the vaccine can be used in advance.